JP2018507191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507191A5 JP2018507191A5 JP2017539592A JP2017539592A JP2018507191A5 JP 2018507191 A5 JP2018507191 A5 JP 2018507191A5 JP 2017539592 A JP2017539592 A JP 2017539592A JP 2017539592 A JP2017539592 A JP 2017539592A JP 2018507191 A5 JP2018507191 A5 JP 2018507191A5
- Authority
- JP
- Japan
- Prior art keywords
- carbocyclyl
- alkyl
- group
- independently selected
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCOC(*C(C(c1cc(N)ccc1)(C#C1)O)(F)F)c2c(C)[n]c3c2C1=CN(C)C3=O Chemical compound CCOC(*C(C(c1cc(N)ccc1)(C#C1)O)(F)F)c2c(C)[n]c3c2C1=CN(C)C3=O 0.000 description 9
- IQMAPSPJMJBMDE-UHFFFAOYSA-N CC#CC(CCN1C)(C1=O)O Chemical compound CC#CC(CCN1C)(C1=O)O IQMAPSPJMJBMDE-UHFFFAOYSA-N 0.000 description 2
- YLTBELHWTNPGRW-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCC1C=CC(C)=CC1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCC1C=CC(C)=CC1)=O)=CN(C)C2=O)O YLTBELHWTNPGRW-UHFFFAOYSA-N 0.000 description 2
- RAJGCIKQGOENJW-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(C(F)(F)F)cccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(C(F)(F)F)cccc1)=O)=CN(C)C2=O)O RAJGCIKQGOENJW-UHFFFAOYSA-N 0.000 description 2
- XOLLFMCFALREEU-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(CO)cccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(CO)cccc1)=O)=CN(C)C2=O)O XOLLFMCFALREEU-UHFFFAOYSA-N 0.000 description 2
- HFYQNRSYAWQQRR-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cc(C)ccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cc(C)ccc1)=O)=CN(C)C2=O)O HFYQNRSYAWQQRR-UHFFFAOYSA-N 0.000 description 2
- MSFKCFKDHJSNQB-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1C#N)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1C#N)=O)=CN(C)C2=O)O MSFKCFKDHJSNQB-UHFFFAOYSA-N 0.000 description 2
- SAKYLTWEJWVZAV-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1F)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1F)=O)=CN(C)C2=O)O SAKYLTWEJWVZAV-UHFFFAOYSA-N 0.000 description 2
- AVNTZJIUDHCKNG-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1OC)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1OC)=O)=CN(C)C2=O)O AVNTZJIUDHCKNG-UHFFFAOYSA-N 0.000 description 2
- NYCGYYJZUVZQTI-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cccnc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cccnc1)=O)=CN(C)C2=O)O NYCGYYJZUVZQTI-UHFFFAOYSA-N 0.000 description 2
- POLAKSSHSXWZGI-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccncc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccncc1)=O)=CN(C)C2=O)O POLAKSSHSXWZGI-UHFFFAOYSA-N 0.000 description 2
- AJJOEXOTNASJST-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ncccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ncccc1)=O)=CN(C)C2=O)O AJJOEXOTNASJST-UHFFFAOYSA-N 0.000 description 2
- OKEVXNFLBCGCIO-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(C3COCC3)[o]1)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(C3COCC3)[o]1)=CN(C)C2=O)O OKEVXNFLBCGCIO-UHFFFAOYSA-N 0.000 description 2
- CILXKLDXJWNCPX-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(CN(C)C)[o]1)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(CN(C)C)[o]1)=CN(C)C2=O)O CILXKLDXJWNCPX-UHFFFAOYSA-N 0.000 description 2
- OQUROCJCZCKXKM-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1C(OCc1ncc[s]1)=O)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1C(OCc1ncc[s]1)=O)=CN(C)C2=O)O OQUROCJCZCKXKM-UHFFFAOYSA-N 0.000 description 2
- ZTRBROBBXVORHK-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1CC1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1CC1)O)=CN(C)C2=O)=O ZTRBROBBXVORHK-UHFFFAOYSA-N 0.000 description 2
- COMPRHAFQLQOPF-UHFFFAOYSA-N Cc1c(C(OCc2c(C)cccc2)=O)c(C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C2=O)c2[nH]1 Chemical compound Cc1c(C(OCc2c(C)cccc2)=O)c(C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C2=O)c2[nH]1 COMPRHAFQLQOPF-UHFFFAOYSA-N 0.000 description 2
- RYWWAEDUMRXXEI-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cc(-c(cccc2)c2OC)ccc1)O Chemical compound CC#CC(C(F)(F)F)(c1cc(-c(cccc2)c2OC)ccc1)O RYWWAEDUMRXXEI-UHFFFAOYSA-N 0.000 description 1
- ZAVOCVZBZQKNKE-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cc(-c2cnccc2)ccc1)O Chemical compound CC#CC(C(F)(F)F)(c1cc(-c2cnccc2)ccc1)O ZAVOCVZBZQKNKE-UHFFFAOYSA-N 0.000 description 1
- AIYYJCAJGGLCJD-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cc(C(N)=O)ccc1)O Chemical compound CC#CC(C(F)(F)F)(c1cc(C(N)=O)ccc1)O AIYYJCAJGGLCJD-UHFFFAOYSA-N 0.000 description 1
- BBXFEKJFMMPSFU-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cccc(N2CCOCC2)c1)O Chemical compound CC#CC(C(F)(F)F)(c1cccc(N2CCOCC2)c1)O BBXFEKJFMMPSFU-UHFFFAOYSA-N 0.000 description 1
- DSSZEQSNKPWVIJ-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cccc(Oc2ccccc2)c1)O Chemical compound CC#CC(C(F)(F)F)(c1cccc(Oc2ccccc2)c1)O DSSZEQSNKPWVIJ-UHFFFAOYSA-N 0.000 description 1
- SVBRMILORLIJCN-UHFFFAOYSA-N CC#CC(CC1)(c2c1cccn2)O Chemical compound CC#CC(CC1)(c2c1cccn2)O SVBRMILORLIJCN-UHFFFAOYSA-N 0.000 description 1
- GHIBGXUHDGMVQN-UHFFFAOYSA-N CC#CC(c(cccc1)c1N1C)(C1=O)O Chemical compound CC#CC(c(cccc1)c1N1C)(C1=O)O GHIBGXUHDGMVQN-UHFFFAOYSA-N 0.000 description 1
- UTISCLIDFORRJP-UHFFFAOYSA-N CC#CC1(CCCCC1)O Chemical compound CC#CC1(CCCCC1)O UTISCLIDFORRJP-UHFFFAOYSA-N 0.000 description 1
- FQTRQGLOMXZYRW-UHFFFAOYSA-N CC#CC1(CCOCC1)O Chemical compound CC#CC1(CCOCC1)O FQTRQGLOMXZYRW-UHFFFAOYSA-N 0.000 description 1
- GNJQQUZKWGDHCB-UHFFFAOYSA-N CC#Cc1cccc(O)c1 Chemical compound CC#Cc1cccc(O)c1 GNJQQUZKWGDHCB-UHFFFAOYSA-N 0.000 description 1
- CDRHEAQGERWKJT-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1-c1nnc(C)[o]1)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1-c1nnc(C)[o]1)=CN(C)C2=O)O CDRHEAQGERWKJT-UHFFFAOYSA-N 0.000 description 1
- QTQNNPUOOYLCIW-UHFFFAOYSA-N CC(C)(C)NC(N(C)C)=O Chemical compound CC(C)(C)NC(N(C)C)=O QTQNNPUOOYLCIW-UHFFFAOYSA-N 0.000 description 1
- ZTKSREVAFIAEHL-UHFFFAOYSA-N CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 ZTKSREVAFIAEHL-UHFFFAOYSA-N 0.000 description 1
- OZWRPGVUTGFIAO-UHFFFAOYSA-N CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 OZWRPGVUTGFIAO-UHFFFAOYSA-N 0.000 description 1
- ILWOKHFPQCOUFS-UHFFFAOYSA-N CC(C)Cc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)Cc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 ILWOKHFPQCOUFS-UHFFFAOYSA-N 0.000 description 1
- PDUSWJORWQPNRP-UHFFFAOYSA-N CC(C)NC(C)=O Chemical compound CC(C)NC(C)=O PDUSWJORWQPNRP-UHFFFAOYSA-N 0.000 description 1
- DUDIPXYIILKDKL-UHFFFAOYSA-N CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 DUDIPXYIILKDKL-UHFFFAOYSA-N 0.000 description 1
- WVBZAVCHGVOIMZ-UHFFFAOYSA-N CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)[F]CCOC(c2c(C)[nH]c4c2C(C#CC(C2F)(c5ccccc5C2=C)O)=CN(C)C4=O)=O)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)[F]CCOC(c2c(C)[nH]c4c2C(C#CC(C2F)(c5ccccc5C2=C)O)=CN(C)C4=O)=O)(c2ccccc2)O)=CN(C)C3=O)[o]1 WVBZAVCHGVOIMZ-UHFFFAOYSA-N 0.000 description 1
- NCNRTTXMYNBOSU-UHFFFAOYSA-N CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 NCNRTTXMYNBOSU-UHFFFAOYSA-N 0.000 description 1
- ZDUBCPAENRAHNV-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc[o]1)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc[o]1)=CN(C)C2=O)O ZDUBCPAENRAHNV-UHFFFAOYSA-N 0.000 description 1
- LWDCCYHOADNXGR-UHFFFAOYSA-N CC(C1CCOCC1)(C#CC)O Chemical compound CC(C1CCOCC1)(C#CC)O LWDCCYHOADNXGR-UHFFFAOYSA-N 0.000 description 1
- IUUDENXUSWKSSU-OFARCZAXSA-N CC(CCc1cc([C@@](C)(C#CC(c2c3[nH]c(C)c2-c2nnc(C4CC4)[o]2)=CN(C)C3=O)O)n[o]1)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(CCc1cc([C@@](C)(C#CC(c2c3[nH]c(C)c2-c2nnc(C4CC4)[o]2)=CN(C)C3=O)O)n[o]1)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 IUUDENXUSWKSSU-OFARCZAXSA-N 0.000 description 1
- JAUWMBGLPFUMJR-UHFFFAOYSA-N CC(c1ccccc1)(C#CC)O Chemical compound CC(c1ccccc1)(C#CC)O JAUWMBGLPFUMJR-UHFFFAOYSA-N 0.000 description 1
- NEPLNECCNNUJRX-UHFFFAOYSA-N CCN(CC1)CCC1(C#CC(c1c2[nH]c(C)c1C(OCC)=O)=CN(C)C2=O)O Chemical compound CCN(CC1)CCC1(C#CC(c1c2[nH]c(C)c1C(OCC)=O)=CN(C)C2=O)O NEPLNECCNNUJRX-UHFFFAOYSA-N 0.000 description 1
- HAYMIDKYYVULDW-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c(cc1)ccc1N(C)C)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c(cc1)ccc1N(C)C)O)=CN(C)C2=O)=O HAYMIDKYYVULDW-UHFFFAOYSA-N 0.000 description 1
- GMYODIBKFOKUSD-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cccc(Oc3ccccc3)c1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cccc(Oc3ccccc3)c1)O)=CN(C)C2=O)=O GMYODIBKFOKUSD-UHFFFAOYSA-N 0.000 description 1
- XCRRPGBTFDGFHY-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cnccc1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cnccc1)O)=CN(C)C2=O)=O XCRRPGBTFDGFHY-UHFFFAOYSA-N 0.000 description 1
- PZZZGCXHKXMEIQ-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1COCC1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1COCC1)O)=CN(C)C2=O)=O PZZZGCXHKXMEIQ-UHFFFAOYSA-N 0.000 description 1
- XXSMVTRJNJTNEP-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C1F)(c3ccccc3C1=C)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C1F)(c3ccccc3C1=C)O)=CN(C)C2=O)=O XXSMVTRJNJTNEP-UHFFFAOYSA-N 0.000 description 1
- KGANURWDWKINIY-FQEVSTJZSA-N CCOC(c1c(C)[nH]c2c1C(C#C[C@@](C)(c1ncccn1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#C[C@@](C)(c1ncccn1)O)=CN(C)C2=O)=O KGANURWDWKINIY-FQEVSTJZSA-N 0.000 description 1
- JUUMTYGPWSCEQD-UHFFFAOYSA-N CCc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CCc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 JUUMTYGPWSCEQD-UHFFFAOYSA-N 0.000 description 1
- CULPBDKFGLEGBW-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C)[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C)[o]1 CULPBDKFGLEGBW-UHFFFAOYSA-N 0.000 description 1
- VHIOSRHANFWGLA-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C2CC2)[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C2CC2)[o]1 VHIOSRHANFWGLA-UHFFFAOYSA-N 0.000 description 1
- MLHPFLGFGSTYNO-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(CCN(C)C)[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(CCN(C)C)[o]1 MLHPFLGFGSTYNO-UHFFFAOYSA-N 0.000 description 1
- XEXSQVGAQDRAMI-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc[o]1 XEXSQVGAQDRAMI-UHFFFAOYSA-N 0.000 description 1
- UNPXNUFUHNWFBO-UHFFFAOYSA-N Cc(cccc1)c1-c1cccc(C(C(F)(F)F)(C#CC)O)c1 Chemical compound Cc(cccc1)c1-c1cccc(C(C(F)(F)F)(C#CC)O)c1 UNPXNUFUHNWFBO-UHFFFAOYSA-N 0.000 description 1
- NZIPEXQUTDPBDQ-UHFFFAOYSA-N Cc1cc(C(C(F)(F)F)(C#CC)O)cc(O)c1 Chemical compound Cc1cc(C(C(F)(F)F)(C#CC)O)cc(O)c1 NZIPEXQUTDPBDQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109522P | 2015-01-29 | 2015-01-29 | |
| US62/109,522 | 2015-01-29 | ||
| PCT/US2016/015450 WO2016123391A1 (en) | 2015-01-29 | 2016-01-28 | Therapeutic compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507191A JP2018507191A (ja) | 2018-03-15 |
| JP2018507191A5 true JP2018507191A5 (enExample) | 2019-03-07 |
| JP6709792B2 JP6709792B2 (ja) | 2020-06-17 |
Family
ID=55361971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539592A Expired - Fee Related JP6709792B2 (ja) | 2015-01-29 | 2016-01-28 | 治療用化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10202378B2 (enExample) |
| EP (1) | EP3250571B1 (enExample) |
| JP (1) | JP6709792B2 (enExample) |
| CN (1) | CN107531692B (enExample) |
| WO (1) | WO2016123391A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| JP7140751B2 (ja) * | 2016-08-24 | 2022-09-21 | エフ．ホフマン－ラ ロシュ アーゲー | ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法 |
| CN109863142B (zh) * | 2016-08-24 | 2022-06-10 | 豪夫迈·罗氏有限公司 | 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法 |
| US11171132B2 (en) * | 2019-10-03 | 2021-11-09 | Globalfoundries U.S. Inc. | Bi-directional breakdown silicon controlled rectifiers |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
| CN120136817A (zh) * | 2025-05-16 | 2025-06-13 | 安徽泽升科技股份有限公司 | 一种氧杂环丁烷-3-甲醇和氧杂环丁烷-3-甲醛的制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| AR057986A1 (es) | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2014125408A2 (en) | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| MX2015012158A (es) | 2013-03-11 | 2015-12-01 | Abbvie Inc | Inhibidores de bomodominio tetraciclicos fusionados. |
| UY35395A (es) | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
| BR112015022643A2 (pt) * | 2013-03-12 | 2017-07-18 | Abbvie Inc | inibidores diidro-pirrolpiridinona |
| CN104211639A (zh) * | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| AU2014278172B2 (en) * | 2013-06-12 | 2018-08-09 | Mycovia Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2014206150A1 (en) | 2013-06-28 | 2014-12-31 | Abbvie Inc. | Bromodomain inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
| EP3632915A1 (en) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| EP3247353A4 (en) | 2015-01-23 | 2018-07-04 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
-
2016
- 2016-01-28 EP EP16704984.0A patent/EP3250571B1/en active Active
- 2016-01-28 JP JP2017539592A patent/JP6709792B2/ja not_active Expired - Fee Related
- 2016-01-28 WO PCT/US2016/015450 patent/WO2016123391A1/en not_active Ceased
- 2016-01-28 CN CN201680019098.2A patent/CN107531692B/zh not_active Expired - Fee Related
-
2017
- 2017-07-24 US US15/658,213 patent/US10202378B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507191A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2018510851A5 (enExample) | ||
| JP2017530984A5 (enExample) | ||
| JP2016510748A5 (enExample) | ||
| RU2015142102A (ru) | Соединение для лечения рака | |
| JP2017533250A5 (enExample) | ||
| JP2017526696A5 (enExample) | ||
| JP2016529312A5 (enExample) | ||
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2019522055A5 (enExample) | ||
| SG11201804348SA (en) | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug | |
| JP2019517487A5 (enExample) | ||
| JP2016538257A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2014513046A5 (enExample) | ||
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| JP2017525740A5 (enExample) | ||
| JP2018501287A5 (enExample) | ||
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
| MX2017001620A (es) | Formas cristalinas de inhibidores de glutaminasa. |